GEN Exclusives

More »

GEN News Highlights

More »
Apr 1, 2009

Ocera Licenses Acute Hepatic Encephalopathy Preclinical Treatment from UCLB

  • Ocera Therapeutics purchased rights to University College London Business’ (UCLB) assets and technologies related to a compound for the treatment of acute hepatic encephalopathy (AHE). The company will develop it as its second pipeline compound and refer to it as OCR-002.

    OCR-002 will be investigated as an injectable treatment of AHE in patients with advanced liver cirrhosis and acute liver failure. Clinical trials in patients with AHE due to cirrhosis and acute liver failure will be carried out at University College Hospital as well as other centers in 2009 under funding from the Medical Research Council in the U.K. Ocera is planning to file an IND in late 2009, and U.S. trials will begin in early 2010.

    Research at the University College London demonstrated an acute and sustained reduction of systemic ammonia levels as well as decreased intracranial pressure in models of AHE in acute liver failure and cirrhosis.

Related content


GEN Jobs powered by connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

The Triple Package and Success

One theory for explaining “success," put forward by Amy Chua Jed Rubenfeld, posits cultural traits such as a superiority complex, personal insecurity and impulse control. Union College professors Joshua Hart and Christopher Chabris counter that intelligence, conscientiousness, and economic advantage are the most likely elements of success, regardless of ethnicity. Do you think that Hart-Chabris make a better argument for achieving success than the Chua-Rubenfeld theory?

More »